Adlai Nortye Ltd. - ANL Market Value

Corporate company logo of Adlai Nortye Ltd (ANL)

Adlai Nortye Ltd. (ANL) develops advanced combination therapies to combat resistant tumors. The business relies on stable demand, rendering the asset defensive during recessions, with a market capitalization of 0.62. This price chart demonstrates the scale of the company, which is accelerating its time-to-market through strategic partnerships with the largest pharma behemoths to develop effective targeted therapy regimens.

Adlai Nortye - ANL Market Valuation (period 02/21/2024 - 11/16/2026)

Adlai Nortye - analytical breakdowns and key metrics (ANL)

- market price and analyst price targets:
Analysis of all company metrics:Adlai Nortye Limited ANL
Original product of adlainortye.com

Searching for assets with a fundamental margin of safety begins with an analysis of the aggregate value of all shares. This figure mathematically strips market quotes of emotional noise, reflecting the actual weight of capital. For Adlai Nortye Ltd. (ANL), this parameter reflects the valuation of prospects for targeted cancer therapy. The dynamics of the business's market capitalization reveal the risk of equity dilution during the funding of clinical trials. Investors must correlate the growth of the curve with the actual number of securities.

Competitor analysis

Market Value BeiGene Ltd ONC|Market Capitalization Halozyme Corp HALO|RVMD - Market Value|Market Valuation AAPG|CG Oncology Corp (CGON) - Market Value|Market Capitalization URGN|BCAX (Bicara Corp) - Market Capitalization|Market Valuation Personalis Corp (PSNL)|Market Capitalization ERAS|Market Capitalization delcath.com (DCTH)|Market Value YmAbs YMAB|AURA: Market Capitalization|Candel Therapeutics, Inc. - Market Capitalization|Accuray Inc. (ARAY) - Market Valuation|SELLAS Life Sciences Group Inc. (SLS) - Market Value|Market Value actuatetherapeutics.com (ACTU)|Market Value Citius Oncology|HURA: Market Value|Market Valuation TARA (Protara)|FATE (Fate Therapeutics Corp) - Market Value|Market Capitalization WHWK (Aadi Bioscience Inc)|TCRX - Market Valuation|CSBR: Market Valuation|XBIT - Market Capitalization|CVM: Market Capitalization|OS Therapies Inc - Market Value|RADX (radiopharmtheranostics.com) - Market Capitalization|Market Value Artiva Biotherapeutics, Inc. ARTV|Market Valuation VERU (Veru)|Market Value TPST|Market Value Xilio XLO|Renovaro Inc. (RENB) - Market Value|MURA - Market Value|Market Capitalization Kairos Pharma KAPA|OKUR (OnKure Therapeutics) - Market Valuation|Market Value CytoMed (GDTC)|Market Value Curis|Market Value APLM|Market Value tharimmune.com (THAR)|Market Valuation Advanced Biomed ADVB|Genprex, Inc - Market Valuation|Market Value CLDI|sunshinebiopharma.com - Market Capitalization|Market Value XBIO (xeneticbio.com)|SLRX (Salarius Pharmaceuticals) - Market Valuation|PPBT - Market Capitalization|Market Value American Oncology Network Inc|BGNE (BeiGene) - Market Value|Market Valuation CKPT (Checkpoint Therapeutics, Inc)|ELEV - Market Value|Market Capitalization ICAD (iCAD Inc.)|Ikena (IKNA) - Market Value|NTBL: Market Valuation|VIRX - Market Capitalization|MorphoSys Corp (MOR) - Market Value|Market Valuation NAYA Bio|Market Value Ascentage Pharma Group